215794-11-9

Basic information

• Product Name: 1-(5-bromo-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoro-ethanone
• Synonyms: 1-(5-bromo-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoro-ethanone
• CAS NO: 215794-11-9
• Molecular Weight: 308.098
• Mol File: 215794-11-9.mol

Chemical Properties

• CAS DataBase Reference: 1-(5-bromo-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoro-ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(5-bromo-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoro-ethanone(215794-11-9)
• EPA Substance Registry System: 1-(5-bromo-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoro-ethanone(215794-11-9)

Safety Data

• Hazardous Substances Data: 215794-11-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(5-bromo-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoro-ethanone is utilized as a key intermediate for the synthesis of a wide range of drugs and biologically active molecules. Its unique structure allows for the creation of diverse pharmaceutical compounds with potential therapeutic applications.
Used in Organometallic Chemistry:
1-(5-bromo-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoro-ethanone has been studied for its potential use as a ligand in organometallic chemistry. Its incorporation into organometallic complexes can lead to novel materials with unique properties and applications.
Used in Medicinal Chemistry and Drug Discovery:
Due to its distinctive structural features, 1-(5-bromo-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoro-ethanone may have potential applications in medicinal chemistry and drug discovery. Researchers can leverage its properties to design and develop new drugs with improved efficacy and selectivity.
Used in Synthesis of Complex Organic Molecules:
1-(5-bromo-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoro-ethanone also serves as a valuable building block for the synthesis of complex organic molecules. Its trifluorinated ketone and 5-bromo-3,4-dihydroisoquinolin-2(1H)-yl groups can be used to construct intricate molecular structures with specific functions and properties.

Upstream product

• 50-00-0 formaldehyd 
• 1057246-44-2 N-(2-bromophenethyl)-2,2,2-trifluoroacetamide 
• 215797-81-2 N-(3-bromophenethyl)-2,2,2-trifluoroacetamide 
• 65185-58-2 2-(2-bromophenyl)ethanamine 

Downstream Products

• 81237-69-6 5-bromo-1,2,3,4-tetrahydro-isoquinoline 

Relevant articles and documents

Heterocyclic compound with Wnt signal path inhibitory activity and application thereof

The invention provides a heterocyclic compound with Wnt signal path inhibitory activity. The heterocyclic compound and chemically acceptable salt, isotope, isomer and a crystal structure thereof are provided with a structure shown as the general formula I (see the formula in the description). The invention further provides application of the heterocyclic compound with the Wnt signal path inhibitory activity. The heterocyclic compound with the Wnt signal path inhibitory activity serves as effective antagonist of a Wnt signal path, and can be used for treating or preventing diseases caused by abnormity of the Wnt signal path.

ARYL LINKED IMIDAZOLE AND TRIAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG

The present invention relates to aryl linked imidazole and triazole derivatives, compositions comprising said compounds, alone or in combination with other drugs, and methods of using the compounds for improving the pharmacokinetics of a drug. The compounds of the invention are useful in human and veterinary medicine for inhbiting CYP3A4 and for improving the pharmacokinetics of a therapeutic compound that is metabolized by CYP3A4.

ARYL LINKED IMIDAZOLE AND TRIAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG

The present invention relates to aryl linked imidazole and triazole derivatives, compositions comprising said compounds, alone or in combination with other drugs, and methods of using the compounds for improving the pharmacokinetics of a drug. The compounds of the invention are useful in human and veterinary medicine for inhbiting CYP3A4 and for improving the pharmacokinetics of a therapeutic compound that is metabolized by CYP3A4.

PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS

The present invention relates to pyrazole oxadiazoles derivatives of Formula (I), and their use for treating multiple sclerosis and other diseases. Wherein R1, R2 and R3 are as defined in the description.

1,2,3,4-Tetrahydropyrazin-2-yl acetamides and methods of use

Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and